Nuclear factor IA (NFIA) is a transcription factor that specifies glial cell identity and promotes astrocyte differentiation during embryonic development. Its expression and function in gliomas are not known. Here, we examined NFIA protein expression in gliomas and its association with clinical outcome in pediatric malignant astrocytomas. We analyzed expression of NFIA by immunohistochemistry in 88 existing glioma specimens from Childrens Hospital Los Angeles and the University of Southern California. Association between NFIA expression and progression-free survival (PFS) was examined in high-grade astrocytomas for which clinical data were available (n 5 23, all children). NFIA was highly expressed in astrocytomas of all grades, but only in a minority of cells in oligodendroglial tumors. NFIA was expressed on a higher percentage of tumor cells in low-grade astrocytomas (91 + + + + + 5% and 77 + + + + + 14% in World Health Organization [WHO] I and II, respectively) compared with high-grade astrocytomas (48 + + + + + 18% and 37 + + + + + 16% in WHO III and IV, respectively; P < .001, low-vs high-grade astrocytomas). There was a significant association between NFIA expression and PFS in children with astrocytoma WHO grade III or IV (Cox regression P 5 .019; logrank trend test for NFIA tertiles P 5 .0040 and NFIA quartiles P 5 .014). The association was not consistently significant in this small series of patients after adjustment was made for WHO grade III or IV. This is the first study to demonstrate expression of NFIA protein in astrocytomas and its association with grades of astrocytoma and PFS, suggesting that NFIA may play a role in astrocytoma biology.
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Keywords: astrocytoma, glioma, nuclear factor IA (NFIA), pediatric, progression-free survival G liomas are the most common primary central nervous system (CNS) tumors in humans, accounting for 40% -50% of all primary intracranial neoplasms. 1 Gliomas contribute significantly to morbidity and mortality in every age group, and prognosis of patients with malignant glioma remains dismal. 2 -5 Traditionally gliomas, tumors of glial origin, are classified on the basis of cellular morphology and proliferation. 6 According to the World Health Organization (WHO) classification, gliomas can be subdivided into astrocytomas, oligodendrogliomas, or mixed oligoastrocytomas, based on glial sublineage. 6 The nuclear factor I (NFI) family of site-specific DNA-binding proteins (also known as CTF or CATT box transcription factor) are critical regulators of gliogenesis in the developing CNS. 7, 8 NFIA, a member of the NFI family, has been shown to be necessary and sufficient for specification of glial identity in ventricular zone progenitors in the developing murine and avian spinal cord. 7 In addition to a role in glial specification, NFI genes are critical regulators of astrocyte differentiation in brain and spinal cord in rats, likely in part through transcriptional regulation of glial fibrillary acidic protein (GFAP) expression. 8, 9 Furthermore, deletion of NFIA or NFIB yields defects in midline glial cell populations in postnatal mouse brain. 10, 11 Indeed, NFIA is also expressed in midline structures in fetal human forebrains. 12 During glial cell development, NFI genes demonstrate dynamic patterns of expression. At the onset of embryonic gliogenesis, NFI genes are expressed in all glial precursors, and as development proceeds, they are transcriptionally repressed in the oligodendrocyte lineage, whereas their expression is maintained in the astrocyte lineage. 7 Such patterns could potentially be used as a means of identifying cells that exist at different points along the axis of glial cell differentiation. 7 Moreover, the involvement of NFIA in glial development suggests that it may be altered in glial tumors or may even play a role in glioma development. Therefore, as our first step in investigating a possible role for NFIA in gliomas, we analyzed expression of NFIA in glial tumors and its association with patient survival. Our data show that higher expression of NFIA protein in astrocytomas is associated with longer survival, suggesting that NFIA may play a role in the biology of human astrocytomas.
Materials and Methods

Tissue Samples
This retrospective study was approved by the Institutional Review Boards at Childrens Hospital Los Angeles and the University Hospital at University of Southern California (USC). Tissues included were formalin-fixed brain tumor samples that were acquired between 1990 and 2007 from 120 patients at Childrens Hospital Los Angeles or the University Hospital at USC. After pathology review, 9 cases containing insufficient or poorly preserved tumor material were excluded. Also excluded from the analysis was 1 patient with a diagnosis of giant cell glioblastoma, which by some is considered to have a different behavior than glioblastoma multiforme (GBM 
Immunohistochemistry
To examine expression of NFIA, immunohistochemical staining with DAB detection on paraffin-embedded tumor-containing sections was performed using the DAKO Envision þ system (DakoCytomation, Carpinteria, California, K4009). Double-labeled immunohistochemistry for NFIA and GFAP was performed using DAKO Doublestain Envision Kit (DakoCytomation, K1395) according to the manufacturer's specifications. After deparaffinization, heat-based antigen retrieval (10 mM citrate, 998C, 30 minutes) in a steamer was performed on all sections to enhance immunodetection. Non-specific antibody binding was blocked by incubation with a protein-blocking reagent (DAKO) for 20 minutes prior to incubating with a primary antibody. The following antibodies were used: NFIA 1:3000 (rabbit polyclonal, Geneka, now Active Motif w ) and GFAP 1:50 (mouse monoclonal-IgG1, DAKO). The NFIA rabbit polyclonal antibody is directed against amino acids 478 -492 of human NFIA. 13 Specificity of this NFIA antibody (Western blot, immunoabsorption, and knockout tissue analysis) has been demonstrated by Plachez et al. 13 and by the manufacturer (http://www.activemotif.com/catalog/ details/39036.html). Stains replacing NFIA primary antibody with rabbit IgG or lacking the primary antibody were used as negative controls for the NFIA immunohistochemical stains (both gave a negative stain). Hematoxylin and eosin (H&E) staining was performed according to standard procedures.
Scoring of Immunohistochemically Stained Sections
An independent neuropathologist (I.G.-G.) who was blinded to the originally assigned pathological diagnosis and clinical outcome reconfirmed the neuropathologic diagnosis on newly cut paraffin-sections, using the guidelines of the WHO. 6 Quantification of NFIA expression was performed by 2 independent investigators (I.G.-G. and H.-R.S.) who were blinded to each other's analysis, to the diagnosis, and to the WHO grade assigned to the sample. NFIA expression was quantified by counting the number of tumor cells that expressed NFIA as a percentage of the total number of tumor cells counted within 3 HPFs (high-power fields; magnification Â400; at least 200 tumor cells per 3 HPFs). Cells with staining of NFIA were interpreted as NFIA-expressing cells. Endothelial cells, which lack NFIA immunoreactivity, were used as an internal negative control. Other negative controls included isotype control antibody in place of the primary antibody and omission of the primary antibody. The value used for statistical analysis was the average of the readings by the 2 counting investigators for each tumor. The inter-investigator variation in percent cells expressing NFIA was less than 10%.
Statistical Analyses
Survival analysis methods, specifically the product limit (Kaplan-Meier) estimate, the logrank test, and Cox regression analysis, 14 were used to evaluate the association of NFIA expression with PFS and OS. PFS was defined as the minimum interval from the date of diagnosis to the date of tumor recurrence, progression, or the last follow-up. OS was defined as the interval from the date of diagnosis to death from any cause or the last follow-up. Several different analyses of the association of PFS with NFIA expression were performed-Cox regression on continuous NFIA; logrank trend test with NFIA grouped by tertiles and quartiles (ie, 3 or 4 nearly equalsized groups)-to examine the consistency of the result. One-way analysis of variance (ANOVA) was used to test the difference in percentage of cells expressing NFIA by tumor grade. 15 Statistical computation was performed using Stata 9.2 16 and Prism GraphPad 5.0 for MacIntosh (GraphPad Software, San Diego, California). Query of the Cancer Genome's Atlas Repository of Molecular Brain Neoplasia Data (REMBRANDT; http://caintegrator-info.nci.nih.gov/rembrandt) was performed on December 3, 2008, according to the instructions on the website, using NFIA as the search term.
Results
NFIA is Expressed in Human Astrocytes
NFIA is a transcription factor that determines astroglial cell fate during early development and is expressed in cells of astrocytic lineage in developing murine and avian embryos. 7 To determine whether NFIA was also expressed in normal human astrocytes, we analyzed normal non-neoplastic brains by immunohistochemistry (n ¼ 10; Fig. 1 ). Indeed, NFIA was expressed in approximately 10% -20% of cells in the lower layers (layers 5 -6) of normal human cerebral cortex and in white matter ( Fig. 1A and C) . Expression was exclusively nuclear. Interestingly, NFIA expression was higher in the subventricular zone (SVZ; 30% -40% of cells; Fig. 1B) . Histologically, NFIA-stained cells showed features of astrocytes, with larger nuclei and abundant cytoplasm compared with oligodendrocytes. Double immunolabeling with NFIA and GFAP (marker for differentiated astrocytes) demonstrated that NFIA was predominantly (80%-90%) expressed in GFAP-positive cells in the normal cerebral cortex (arrows, Fig. 1D ). In the cerebral cortex, NFIA was not expressed in neurons (GFAP-negative large cells with central nucleus; arrowheads, Fig. 1D ). These data indicate that in normal human cerebral cortex, NFIA is predominantly expressed in cells of astrocytic lineage.
NFIA is Differentially Expressed in Human Astrocytomas
Given that NFIA marks cells of astrocytic lineage, we next examined expression of NFIA in human astrocytomas (n ¼ 74) using immunohistochemistry, as described in Materials and Methods. Figure 2 shows that NFIA was expressed in nuclei of tumor cells in all grades of astrocytoma. Interestingly, we found an inverse association between the percentage of tumor cells expressing NFIA and the WHO grade of the astrocytomas, with higher proportion of NFIA-expressing tumor cells in the lower-grade astrocytomas (P , .001, lowgrade astrocytomas vs high-grade astrocytomas, Fig. 2 and Table 2 ). In both pilocytic astrocytoma (WHO grade I) and astrocytoma (WHO grade II), we found cells expressing NFIA uniformly throughout the tumor ( Fig. 2A) , with all pilocytic tumors uniformly expressing NFIA in over 80% of the tumor cells. The other astrocytoma grades had greater heterogeneity of NFIA expression among tumors within the same grade (Fig. 2B) . Of the 12 GBMs we analyzed, 2 demonstrated perivascular invasion of tumor cells around the tumor border. Interestingly, the perivascularly infiltrating tumor cells expressed NFIA at an exceptionally large proportion compared with tumor cells within the main tumor mass (Fig. 3) . This expression pattern suggests that NFIA may play a yet-unknown role in astrocytoma biology, and possibly in invasion.
NFIA is Expressed Only Minimally in Oligodendrogliomas
During embryonic development, NFIA is expressed mostly in cells of astrocyte lineage, but less so in cells of oligodendrocyte lineage. 7 Therefore, we next compared NFIA expression in the astrocytomas with expression in nonastrocytic gliomas: 12 oligodendroglial tumors and 2 oligoastrocytomas (mixed glial tumors; Fig. 4 ). In the oligoastrocytomas we examined (immunohistochemistry), only cells with astrocytic features (increased pleomorphism and atypia; arrows) expressed NFIA, whereas cells with oligodendroglial features (round nuclei and perinuclear halos; arrowheads) did not express NF1A (Fig. 4, top panel) . Quantification of NFIA-expressing cells in the oligodendrogliomas revealed that a mean of only 4.0 + 3% of all tumor cells expressed NFIA (Figs 2B and 4 middle and bottom panels). This expression was significantly lower than the expression of NFIA we found in astrocytomas (P , .001). Similarly, in the nonglial brain tumors we examined (schwannomas, lymphomas, and meningiomas, n ¼ 4 tumors for each type), NFIA was also expressed in less than 3% of the tumor cells (Table 2 and Supplementary Material, Fig. S1 ). Taken together, these data demonstrate that although NFIA was highly expressed in astrocytomas, it was minimally expressed in oligodendrogliomas and in nonglial brain tumors.
Expression of NFIA is Associated with PFS in Malignant Astrocytomas
Our immunohistochemistry data show that in malignant astrocytomas (anaplastic astrocytoma and GBM, WHO III and IV, respectively), NFIA was expressed in fewer of the tumor cells compared within low-grade astrocytomas (WHO grade I and II), where it was highly expressed (Fig. 2B ). This suggested that higher NFIA expression may be associated with better survival. We therefore asked whether NFIA expression was also inversely associated with outcome among the malignant Fig. 2 . NFIA is highly expressed in human astrocytomas. (A) H&E and immunohistochemistry for NFIA of 4 representative pediatric astrocytomas WHO grades I -IV. Left column is H&E stain (Â400), middle column is anti-NFIA stain (Â400), and right column is a 2-fold magnification of the inset from the middle column. Endothelial cells, which lack NFIA immunoreactivity, were used as an internal negative control (arrowheads). (B) Quantification of NFIA expression in pediatric and adult gliomas and normal brains. Bars represent mean + SD for pilocytic astrocytoma (I, n ¼ 21), astrocytoma (II, n ¼ 21), anaplastic astrocytoma (III, n ¼ 20), and GBM (IV, n ¼ 12). Comparison is with nontumor containing cerebrum (NL, n ¼ 10), oligodendroglioma (II, n ¼ 7), and anaplastic oligodendroglioma (III, n ¼ 5). *P , .0001 in the continuum of the 4 WHO grades of astrocytoma (one-way ANOVA) and P , .001 between the low-grade (WHO I and II) and the high-grade (WHO III and IV) astrocytomas (Student's t-test). P value is also ,.0001 between astrocytomas and oligodendrogliomas (t-test). See Table 2 for details. WHO III and IV astrocytomas, both of which carry a poor prognosis. We first analyzed the publicly available REMBRANDT 17 of the Cancer Genome Atlas, which contains microarray expression and OS data for adult patients with GBM. Data are available for NFIA expression using 4 probesets and are compared with nontumor brain samples. Analyzing these data, we found that in 2 of the 4 NFIA probesets, patients whose GBM (WHO grade IV astrocytoma) had a high NFIA mRNA level (defined as !2-fold upregulated compared with non-tumor samples) benefited from significantly longer OS (P , .05) compared with patients whose GBM NFIA level was intermediate (defined as expression level between 2-fold upregulated and 2-fold downregulated compared with nontumor samples; probesets 224976_at and 224970_at; Fig. 5 ). Only 1 of the 4 probesets (1557639_at) had sufficient number of GBM patients with low NFIA expression level (defined as NFIA dowregulated !2-fold compared with nontumor tissues; n ¼ 16 patients with downregulated NFIA). This probeset showed that low NFIA expression was significantly associated with worse OS when compared with intermediate NFIAor high NFIA-expressing GBMs (Fig. 5) . One probeset (224975_at) did not show a significant difference in (Fig. 5 ). This suggests that in adult patients with GBM, higher NFIA expression in the tumor was associated with improved OS. These findings prompted us to examine PFS and OS of the patients with WHO III and IV astrocytomas whose tumors were analyzed in Fig. 2 and whose clinical information was available (n ¼ 23, all pediatric patients at Childrens Hospital Los Angeles). In these 23 pediatric patients, PFS was significantly associated with NFIA expression in univariate Cox regression (P ¼ .019, continuous NFIA). When dividing NFIA expression into either 3 or 4 groups that are as equal as possible, PFS was also significantly associated with NFIA expression (tertiles: P ¼ .0040, quartiles: P ¼ .014, logrank test for trend, Fig. 6 ). PFS association with NFIA was not significant if the group was divided at the median (P . .10), but 2-group comparisons of continuous variables are known to be inefficient. 18 The association also was not consistently significant in these analyses when adjustment was made for WHO grade III vs IV, although all of these analyses nominally showed lower failure risk with higher NFIA expression. Figure 6 and Table 3 show the difference in PFS and OS among these 23 pediatric patients. There was no significant association between NFIA expression and OS in this small series (P . .10, logrank test for trend), in which 1 patient died of pneumonia without evidence of disease 3 months from diagnosis and another was lost to follow-up less than 2 months after surgery. Interestingly, in the much larger REMBRADNT adult GBM mRNA microarray data set presented above (Fig. 5) , higher NFIA was associated with longer OS (Fig. 5) , corroborating the PFS data calculated based on NFIA protein expression by IHC in the pediatric high-grade astrocytoma patients.
Taken together, our data show that NFIA expression was higher in WHO grade I and II astrocytomas compared with WHO grade III and IV astrocytomas and that in the WHO grade III and IV astrocytomas a higher expression of NFIA was associated with better PFS. Interestingly, NFIA expression was only minimal in oligodendrogliomas compared with the astrocytomas.
Discussion
The goal of our study was to assess expression of the glial fate determinant NFIA in human gliomas compared with normal brain and nonglial brain tumors. We also examined whether NFIA expression was associated with survival.
Our data show that NFIA was differentially expressed in astrocytomas: it was highly expressed in the low-grade astrocytomas (WHO I and II) compared Fig. 2B . In oligoastrocytomas, cells with astrocytic features (increased pleomorphism and atypia; arrows) expressed NFIA, but cells with oligodendroglial features (round nuclei and perinuclear halos; arrowheads) were negative. In the pure oligodendrogliomas (middle and lower panels), only rare cells expressed NFIA.
with the high-grade astrocytomas (WHO III and IV). To date, the only other analysis of NFI genes in gliomas has been in a recent microarray analysis validated by realtime PCR of 20 primary GBMs that found overexpression of NFIA mRNA compared with that of normal brain. 19 However, our data provide the only analysis to date to examine the association of NFIA with survival in astrocytomas or in any other cancer. Interestingly, a link of NFIA to human leukemia was recently reported, with the finding of NFIA mutations of yet-unknown significance in 2 patients with chronic malignant myeloid disease. 20 Although our data suggest involvement of NFIA in astrocytoma biology, the function of NFIA in gliomas is not clear at this time. Since NFIA is required for glial differentiation in embryonic development, 7, 10 it is possible that its higher expression in the more differentiated astrocytomas (WHO I and II) may reflect its role in promoting astrocyte differentiation, providing a possible tumor-suppressive role. On the other hand, the requirement of NFIA for maintenance of the glial progenitor cell pool in embryonic spinal cord 7 may hint at a possible contribution to tumor initiating cells. This suggests a complex mechanism of action that may depend on the genetic and cellular context in which NFIA is expressed, as well as a specific use of one or more of the isoform(s) of NFIA. 8,21 -23 Interestingly, in chicken embryo fibroblasts, NFIA was not oncogenic and its expression even rendered the cells resistant to transformation by nuclear oncogenes, such as jun, fos, and myc (all encoding transcription factors), 24 again suggesting a tumor-resisting function. However, these NFIA expressing chicken cells were readily transformed by cytoplasmic oncogenes, such as src, raf, ras, and fms, 24 indicating retention of a tumor-permissive role for certain signaling pathways. If a dual role is found for NFIA in astrocytomas, this may not be surprising in view of its many isoforms and the complexity of function already known in other transcription factors such as WT1, which originally was discovered as a tumorsuppressor gene, but in another isoform, was later found to have oncogenic function. 25 Alternatively, genetic context may also play a role in determining possible oncogenic/permissive vs tumor-suppressive function of NFIA as demonstrated in certain oncogenes, such as myc and ras, which induce apoptosis in the presence of p53 while promoting transformation in the absence of p53. 26 -28 It is interesting to note that NFI can bind to an element in the p53 promoter that contributes to the basal activity of the promoter function of p53 in a tissue-specific and mutually exclusive manner with YY1, a zinc finger transcription factor that can promote (eg, c-myc) or repress (eg, c-fos) other promoters. 29 Our observation that NFIA protein is highly enriched in perivascular tumor cells in the invasive tumor border compared with nonperivascular tumor cells within the main GBM mass suggests that in high-grade astrocytomas, NFIA may function (either positively or negatively) in tumor cell invasion and/or migration. Consistent with a role of NFIA in migration, the adhesion molecules ephrin B1 and N-cadherin were recently found to be targets of NFIA in cerebellar granular neurons. 30 Identification of markers that distinguish astrocytomas from oligodendroglial tumors has long been a goal of neuropathologists and neuro-oncologists. However, markers, such as Olig2 and STAT3, which are thought to function in glioma formation, are similarly expressed in both astrocytomas and oligodendrogliomas, precluding their diagnostic use. 31, 32 Therefore, our observation that NFIA was expressed in all grades of astrocytomas, but only minimally in oligodendrogliomas is interesting, Table 3 . and suggests that future studies may find NFIA to be a useful diagnostic marker to distinguish between these 2 glial tumors. Supporting this, preliminary examination of a small number of oligodendroglial tumors showed that cellular expression of NFIA and the oligodendroglial marker, Olig2 were mutually exclusive (data not shown, unpublished data). These data are consistent with developmental expression patterns, where NFIA is preferentially expressed in astrocytes but not in oligodendrocytes. Interestingly, during some stages of spinal cord development, Olig2 antagonizes the ability of NFIA to promote astrocyte differentiation, and the suppression of Olig2 by NFIA seems to depend on the relative levels of the 2 proteins. 7 Additionally, Olig2 can transcriptionally repress NFIA expression. In the Olig2 2 /2 mouse, there is a derepression of NFIA expression, suggesting that in oligodendrogliomas Olig2 may transcriptionally repress NFIA expression (B.D., unpublished data). A more comprehensive study is needed to determine whether NFIA may be useful as a diagnostic astrocytic marker to differentiate astrocytic tumors from oligodendroglial tumors in cases that are difficult to assess based on morphology alone.
Our demonstration that NFIA protein expression in astrocytomas is associated with longer PFS was significant despite the relatively small group of patients available for analysis of PFS (n ¼ 23 children). Larger-scale studies, such as those possible in adult patients, will be needed in order to determine whether NFIA may be a potential prognostic marker in high-grade astrocytomas. Our immunohistochemical results are supported by the analysis of the publicly available REMBRANDT microarray data set (Fig. 5) , which showed that OS was longer in adult patients whose GBM tumors expressed !2-fold higher NFIA mRNA (relative to NFIA in nontumor samples), when compared with GBM patients with intermediate or low NFIA. Scrideli et al. 19 showed by quantitative real-time PCR that expression of NFIA mRNA in 20 GBMs was more than 13 times higher than in 10 samples of non-neoplastic white matter, but did not examine association with PFS or OS. Our immunohistochemistry results showed that the fraction of cells expressing NFIA in GBM was higher than in the normal brain ( Fig. 2B, P , .001 ) corroborating the data of Scrideli et al. 19 at the protein level. The findings of Schuur et al. 24 that NFIA expression in chick embryo fibroblasts renders them resistant to transformation by nuclear oncogenes may hint at a mechanism that may be related to our findings of association of higher NFIA with improved outcome in the high-grade astrocytomas and its higher expression in the low-grade astrocytomas. The protection from transformation by NFIA in the chick embryo fibroblasts may suggest that retention of NFIA in astrocytoma may protect cells from further transforming events, whereas its loss (or perhaps its cytoplasmic localization) may expose the cells to increased susceptibility to further malignant transformation. 24 In summary, our data demonstrate differential expression of NFIA in low-vs high-grade astrocytomas and association between NFIA protein expression and improved PFS in children with high-grade astrocytomas. This is supported by the analysis of the REMBRANDT GBM microarray database. These findings, combined with current knowledge, suggest that NFIA may have an important role in astrocytoma biology.
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